CD8A and malignant colon neoplasm: Similarly, a randomized controlled study of neoadjuvant ipilimumab and nivolumab for early-stage colon cancer showed that ICI responders had higher baseline CD8+PD-1+ T-cell infiltration and TCR clonality [40].